171 related articles for article (PubMed ID: 21273636)
1. Paradoxical decrease in serum high-density lipoprotein cholesterol and lipid-lowering drugs.
Crook MA
Ann Clin Biochem; 2011 Jan; 48(Pt 1):3-4. PubMed ID: 21273636
[No Abstract] [Full Text] [Related]
2. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
Golomb B; Evans M
Drug Saf; 2006; 29(12):1191; author reply 1191-2. PubMed ID: 17147465
[No Abstract] [Full Text] [Related]
4. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
5. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I.
Crouse JR; Frohlich J; Ose L; Mercuri M; Tobert JA
Am J Cardiol; 1999 May; 83(10):1476-7, A7. PubMed ID: 10335764
[TBL] [Abstract][Full Text] [Related]
6. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
7. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
[TBL] [Abstract][Full Text] [Related]
8. Intensive lipid lowering with atorvastatin in coronary disease.
Ravnskov U; Rosch PJ; Sutter MC
N Engl J Med; 2005 Jul; 353(1):93-6; author reply 93-6. PubMed ID: 16003834
[No Abstract] [Full Text] [Related]
9. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
10. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.
Alsheikh-Ali AA; Karas RH
Am J Cardiol; 2004 Jun; 93(11):1417-8, A9. PubMed ID: 15165929
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
Jafari M; Ebrahimi R; Ahmadi-Kashani M; Balian H; Bashir M
J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):123-6. PubMed ID: 12808485
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
14. High-dose statins and the IDEAL study.
Ravnskov U; Rosch PJ; Sutter MC
JAMA; 2006 Jun; 295(21):2476; author reply 2478-9. PubMed ID: 16757714
[No Abstract] [Full Text] [Related]
15. High-dose statins and the IDEAL study.
Cayley WE
JAMA; 2006 Jun; 295(21):2476; author reply 2478-9. PubMed ID: 16757713
[No Abstract] [Full Text] [Related]
16. High-dose statins and the IDEAL study.
Ong HT; Cheah JS
JAMA; 2006 Jun; 295(21):2476-7; author reply 2478-9. PubMed ID: 16757712
[No Abstract] [Full Text] [Related]
17. Tachyphylaxis and statin drugs.
Stein JH; McBride PE
Am J Cardiol; 2001 Mar; 87(5):674. PubMed ID: 11245286
[No Abstract] [Full Text] [Related]
18. [Statins after drug discontinuation are usually well tolerated].
Steurer J
Praxis (Bern 1994); 2013 Jun; 102(13):813. PubMed ID: 23773943
[No Abstract] [Full Text] [Related]
19. Statin therapy after stroke or transient ischemic attack.
Cohen JS
N Engl J Med; 2006 Nov; 355(22):2368; author reply 2370-1. PubMed ID: 17135593
[No Abstract] [Full Text] [Related]
20. The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
S Afr Med J; 2002 Aug; 92(8):596-7. PubMed ID: 12244613
[No Abstract] [Full Text] [Related]
[Next] [New Search]
